A Comprehensive Nutriceutical Approach to Metabolic and Vascular Health

Abstract

A composite nutriceutical containing extracts of Momordica charantia, pine bark extract, hematococcus pluvialis, red yeast rice, the antioxidants alpha-lipoic acid and oxidoreductase ubiquinone Q10, vitamins B9 and B12, and selenomethionine was given to 23 patients suffering from hyperinsulinemia and/or hyperlipemia as part of an open-label prospective cohort trial.Treatment induced significant and persistent reduction of serum concentrations of insulin, C-peptide, glycated haemoglobin A1c, gamma-glutamyl transpeptidase, total and LDL cholesterol during 12 months of intake. Two patients interrupted treatment because of gastro-intestinal side effects. Vital parameters, renal function tests and triglycerids remained unchanged.It is concluded that this composite nutriceutical improves biological markers and may reduce the risk of vascular pathology and non-alcoholic fatty liver disease. This premise needs to be confirmed by controlled clinical trials.